1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • González-Martínez S, Palacios J, Carretero-Barrio I, Fernández-Lanza V, Cortés-Salgado A, Román J, Matias-Guiu X, Gatius S, Cortés J, Pérez-Mies B.

    Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.

    JOURNAL OF PATHOLOGY . 268(2): 227-242.

    [doi:10.1002/path.70003]

  • Borrego MR, López-Bravo DP, Vila MM, Pérez-García JM, Fernández M, Tormo SB, García-Saenz JÁ, Lema L, Garau I, Cortez P, Torres AA, Conejo EA, Calvo I, Ferrer N, Blancas I, Amillano K, Santasusagna S, Benderra MA, Alcalá-López D, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J.

    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study

    EUROPEAN JOURNAL OF CANCER . 233: 116161-116161.

    [doi:10.1016/j.ejca.2025.116161]

  • Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthélémy P, Voog E, Cutuli HJ, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK.

    Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

    LANCET ONCOLOGY . 27(1): 68-78.

    [doi:10.1016/S1470-2045(25)00566-2]

  • Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Liedke PER, Carroll D, Khan S, Rugo HS, Xu B, Bardia A.

    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study.

    Annals of oncology : official journal of the European Society for Medical Oncology . : .

    [doi:10.1016/j.annonc.2025.12.017]

  • Martín M, Guerrero-Zotano AL, Pérez-López ME, Ruiz-Borrego M, Martinez Jañez N, Chacón JI, Gil-Gil M, Andrés R, Bermejo B, Sánchez-Rovira P, Del Barco S, Ponce JJ, Fernandez I, Martínez de Dueñas E, Hinojo-Gonzále C, González M, García-Garre E, Hernando B, de la Haba-Rodriguez J, Álvarez IM, González-Santiago S, Garcia-Saenz JA, Santaballa A, Casas M, Bezares S, Caballero R, Rojo F, Alba E.

    Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

    CLINICAL CANCER RESEARCH . : .

    [doi:10.1158/1078-0432.CCR-25-2435]

  • Ruz-Caracuel I, Rosell A, Geryková L, Gama JM, Alonso-Gordoa T, Rodríguez-Villena A, Almeida R, Rosas M, Martínez-Hernández R, Martins MJ, Ryska A, Eloy C, Palacios J.

    Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma

    ENDOCRINE PATHOLOGY . 36(1): 49-49.

    [doi:10.1007/s12022-025-09894-9]

  • Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, Sacristán-Gómez P, Sánchez de la Blanca N, Sampedro-Núñez M, Navas-Moreno V, Sebastián-Valles F, Fernández-Alen JA, Biagetti B, Ruz-Caracuel I, Araujo-Castro M, Puig-Domingo M, Marazuela M.

    Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . : .

    [doi:10.1210/clinem/dgaf634]

  • Biagetti B, Cardona-Arias A, Torre EM, Aulinas A, Ruz-Caracuel I, Centeno RG, González L, Echarri AI, Rodríguez MDM, Paja M, Guerrero-Pérez F, Castaño JP, García MDO, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabéu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Rojas-Marcos PM, Recio-Córdova JM, Lozano-Aida C, Roca QA, Aviles MD, Mezquita EL, Argueso MF, Molero IG, Alberoa I, Idrobo C, Achote E, Martínez-Sáez E, Marazuela M, Puig-Domingo M, Hanzu F, Araujo-Castro M.

    Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study

    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION . 48(12): 2857-2867. Nº de citas: 2

    [doi:10.1007/s40618-025-02674-6]

  • Araujo-Castro M, Menéndez Torre E, Aida CL, García-Centeno R, González L, Idrobo C, Achote E, Irigaray Echarri A, Rodríguez-Argulló MDM, Paja M, Guerrero-Pérez F, Castaño JP, Dolores Ollero García M, Novo-Rodríguez C, Tenorio-Jimenéz C, Villar-Taibo R, Bernabeu I, Díaz-López E, Calatayud M, Alvarez-Escola C, Martín-Rojas P, Recio-Córdova JM, Aulinas A, Asla Roca Q, Aviles MD, López Mezquita E, Fernández Argüeso M, González Molero I, Ruz-Caracuel I, Aldecoa I, García J, Martínez-Sáez E, Hanzu F, Marazuela M, Puig-Domingo M, Biagetti B.

    Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(12): 3391-3399. Nº de citas: 6

    [doi:10.1210/clinem/dgaf252]

  • Capdevila J, Hernando J, Molina-Cerrillo J, Benavent Viñuales M, Garcia-Carbonero R, Teulé A, Custodio A, Jimenez-Fonseca P, Lopez C, Hierro C, Carmona-Bayonas A, Alonso V, Llanos M, Sevilla I, Garcia-Alvarez A, Alonso-Gordoa T, Gallego Jiménez I, Antón-Pascual B, Modrego Sánchez A, Grande E.

    Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)

    CLINICAL CANCER RESEARCH . 31(22): 4655-4663. Nº de citas: 1

    [doi:10.1158/1078-0432.CCR-25-2143]

  • Martinez-Jañez N, García-Saenz JÁ, Pernas S, Bermejo B, Morales S, Guerra J, Silva J, Manso L, Ciruelos E, Tolosa P, Sánchez-Bayona R, Alva M, Calabuig-Fariñas S, Gallach S, Muinelo-Romay L, Piñeiro-Yáñez E, Caleiras E, Bueno MJ, Mouron S, Quintela-Fandino M.

    Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations

    npj Precision Oncology . 9(1): 343-343.

    [doi:10.1038/s41698-025-01106-1]

  • Madariaga A, Cots M, Hierro C, Robles C, Garrido S, Barretina-Ginesta MP, Serrano A, Serena M, Salcedo P, Mariátegui N, Guerra E.

    Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-025-04127-1]

  • Smith M, Piulats J, Todenhöfer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Fléchon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    LANCET ONCOLOGY . 26(11): 1489-1500.

    [doi:10.1016/S1470-2045(25)00475-9]

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(11): 3155-3167. Nº de citas: 2

    [doi:10.1210/clinem/dgaf082]

  • Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.

    The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

    Cells . 14(21): .

    [doi:10.3390/cells14211676]

  • Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.

    Autoantibodies are associated with worse outcomes in MASLD

    JHEP REPORTS . 7(10): 101470-101470.

    [doi:10.1016/j.jhepr.2025.101470]

  • Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.

    A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-025-04062-1]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]